Factor VIII Inhibitor - 2018 Pipeline Insights with Detailed Analysis of 2 Active Products: Caplacizumab (Ablynx) and SHP655 (Shire) - ResearchAndMarkets.com
DUBLIN--(BUSINESS WIRE)--Jul 31, 2018--The “Factor VIII Inhibitor - Pipeline Insight, 2018” drug pipelines has been added to ResearchAndMarkets.com’s offering.
This report outlays comprehensive insights of present scenario and growth prospects across Factor VIII Inhibitor.
A detailed picture of the pipeline landscape is provided with summation of data from multiple sources with complete analysis by development stage, mechanism of action, route of administration and molecule type. This report provides detailed analysis of two active products, i.e., Caplacizumab of Ablynx and SHP655 of Shire.
Products Covered by PhaseFiled & Phase III Inactive (Dormant and Discontinued)
Overview of Pipeline Development Activities for Factor VIII InhibitorProvides an overview of therapeutic pipeline activity for Factor VIII Inhibitor across the complete product development cycle including all clinical and non-clinical stages It comprises of detailed profiles of Factor VIII Inhibitor therapeutic products with key coverage of developmental activities including licensing & collaboration deals, patents issued, designations, technologies and chemical information Therapeutic assessment of the active pipeline products by stage, product type, molecule type, and route of administration Coverage of dormant and discontinued pipeline projects across Factor VIII Inhibitor
Companies FeaturedAblynx Shire ThromboGenics Ajinomoto BioVascular Archemix Corporation Glenmark Sanofi
Key Topics CoveredOverview Factor VIII Structure A-Domain B-Domain C-Domain Mechanism of Action Factor VIII Mutation Indications related to Factor VIII Thrombotic thrombocytopenic purpura (TTP) Thrombosis Acute coronary syndrome Factor VIII/ von Willebrand Factor Complex Pipeline Therapeutics Late Stage Products (Filed & Phase III) Comparative Analysis Caplacizumab: Ablynx Product Description Research and Development Product Development Activities Inactive Products Comparative Analysis Appendix
For more information about this drug pipelines report visit https://www.researchandmarkets.com/research/hkd7dg/factor_viii?w=4
View source version on businesswire.com:https://www.businesswire.com/news/home/20180731005622/en/
Laura Wood, Senior Manager
For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
Related Topics:Hematological Drugs
INDUSTRY KEYWORD: HEALTH PHARMACEUTICAL
SOURCE: Research and Markets
Copyright Business Wire 2018.
PUB: 07/31/2018 10:09 AM/DISC: 07/31/2018 10:09 AM